← Back to Clinical Trials
Recruiting NCT07335692

NCT07335692 Dynamical Electrophysiology and Neuropathology in Lewy's Bodies Disease

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07335692
Status Recruiting
Phase
Sponsor University Hospital, Strasbourg, France
Condition Lewy Body Disease
Study Type OBSERVATIONAL
Enrollment 40 participants
Start Date 2025-06-02
Primary Completion 2026-06

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 40 participants in total. It began in 2025-06-02 with a primary completion date of 2026-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Lewy body disease (LBD) is a neurodegenerative disorder that causes cognitive and behavioral problems. However, it is difficult to diagnose, and its pathophysiology is still not fully understood. The usual diagnostic criteria for LBD have excellent specificity but poor sensitivity. In particular, we lack paraclinical tests that can make a significant contribution. LBD patients may exhibit abnormalities in brain activity dynamics, which can be detected by EEG and may be linked to neuronal dysfunctions specific to the disease. The objective of this study is twofold: first, to assess the validity of this observation, that is, to confirm that the observed phenomenon is indeed linked to the pathophysiology of LBD, and second, to clarify the nature of these abnormalities by exploring the brain dynamics of LBD patients in greater detail.

Eligibility Criteria

Inclusion Criteria: * Adult subjects (≥18 years old). * Subject who participated in the Alpha-Lewy-MA cohort and underwent RT-QuIC analysis. * Subject who underwent a standard EEG examination at HUS between January 1, 2012, and January 1, 2020. Exclusion Criteria: \- Subject who expressed opposition to participating in the study.

Contact & Investigator

Central Contact

Ludovic DORMEGNY-JEANJEAN, MD

✉ ludovic.jeanjean@chru-strasbourg.fr

📞 33 3 88 11 69 21

Frequently Asked Questions

Who can join the NCT07335692 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Lewy Body Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07335692 currently recruiting?

Yes, NCT07335692 is actively recruiting participants. Contact the research team at ludovic.jeanjean@chru-strasbourg.fr for enrollment information.

Where is the NCT07335692 trial being conducted?

This trial is being conducted at Strasbourg, France.

Who is sponsoring the NCT07335692 clinical trial?

NCT07335692 is sponsored by University Hospital, Strasbourg, France. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology